|
2010/06/08
Okamoto M, Akiyama S, Tomoda T, Abe H, Tsukada J:
Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan; Kudan Clinic, Toyko, Japan; Seren Clinic,
Tokyo, Japan; Kudan Clinic, Tokyo, Japan; Tella, Inc., Tokyo, Japan
Abstract
Background: Tumor-specific cytotoxic T lymphocytes (CTLs) can be activated in vivo by dendritic cell (DC)- based vaccination.
However, clinical responses to the immunotherapy with DC vaccination have only been observed in a minority of patients with
solid cancer.
Combination with other treatment modalities such as chemotherapy may overcome immunoresistance of cancer cells.
In the current study, the clinical efficacy of the DC vaccine pulsed with the peptide derived from colorectal cancer-associated
antigens in combination with chemotherapy has been evaluated in patients with advanced, inoperable colorectal cancer.
Methods:
Thirty-two patients with advanced, inoperable colorectal cancer refractory to standard treatment were entered into the study.
DCs that were generated from CD14+ monocytes from leukapheresis by 6-day cultivation with granulocyte macrophage-colony
stimulating factor (GM-CSF) and interleukin (IL)-4, were matured by OK-432, a streptococcal agent, and were pulsed with the
pancreatic cancer-associated antigens, such as WT1, MUC1. These DCs (1 x 107) were intradermally administered 5 times at
14- day intervals.
Results:
Of the 32 patients, complete response (CR) was observed in 0 (0%), partial response (PR) in 7 (21.9%), stable disease (SD)
in 12 (37.5%), progressive disease (PD) in 13 (40.6%). Response rate was 21.9%.
Tumor control rate was 59.4%. Survival rate, quality of life, performance status were markedly increased. Severe side effects
of more than grade 3 which were assessed in accordance with NCI-Common Toxicity Criteria v.2.0, were not observed.
Conclusions:
It was strongly suggested that the DC vaccination pulsed with cancer-associated peptides in combination with chemotherapy
was safe and effective in patients with inoperable colorectal cancer refractory to standard treatment.
* 2010 미국 임상종양학회
June 4-8, 2010 Chicago, USA
|
